PMID- 23890221
OWN - NLM
STAT- MEDLINE
DCOM- 20140507
LR  - 20220331
IS  - 1464-410X (Electronic)
IS  - 1464-4096 (Linking)
VI  - 113
IP  - 4
DP  - 2014 Apr
TI  - Copy number aberrations using multicolour fluorescence in situ hybridization 
      (FISH) for prognostication in non-muscle-invasive bladder cancer (NIMBC).
PG  - 662-7
LID - 10.1111/bju.12232 [doi]
AB  - OBJECTIVE: To investigate if detection of copy number aberrations of chromosomes 
      3, 7, 9p21, and 17 using multicolour fluorescence in situ hybridization (FISH) 
      predicts patient outcome in non-muscle-invasive bladder cancer (NMIBC). PATIENTS 
      AND METHODS: In all, 118 bladder wash samples were prospectively collected from 
      patients who underwent transurethral resection of bladder tumour (median age 50.5 
      years, male/female: 91/27, tumour grade 1/2/3: 18/52/42, stage pTis/Ta/T1: 
      8/62/42) from 2007 to 2010. The 118 samples were analysed using the UroVysion(R) 
      kit to detect the copy numbers of chromosomes 3, 7, 9p21, and 17. The variant 
      fraction (VF; the sum of the non-modal copy number fraction of each chromosome) 
      was defined as abnormal when the percentage was >/=16%. The percentage deletion of 
      9p21 (fraction of null or one copy number of the 9p21 locus) was defined as 
      abnormal when the percentage was >/=12%. Maffezzini risk criteria were also 
      analysed in our cohorts. RESULTS: There was recurrence in 57 (48.3%) patients and 
      disease progression in 12 (10.1%), with a median follow-up of 35.7 months. 
      Multivariate analysis showed that the percentage 9p21 loss (>12%) was an 
      independent prognostic factor for recurrence (P < 0.001, odds ratio [OR] 3.24, 
      95% confidence interval [CI] 1.85-5.62). For disease progression, tumour grade, 
      positive urine cytology, concurrent carcinoma in situ, and a mean VF of >16% were 
      significant prognostic factors in univariate analysis. In multivariate analysis, 
      a mean VF of >16% was a prognostic factor for disease progression (P = 0.048, OR 
      6.07, 95% CI 1.02-57.45). CONCLUSIONS: Multicolour-FISH analysis using a 
      commercially available kit could be a powerful tool not only for diagnosis, but 
      also for prognostication in patients with NMIBC.
CI  - (c) 2013 The Authors. BJU International (c) 2013 BJU International.
FAU - Matsuyama, Hideyasu
AU  - Matsuyama H
AD  - Department of Urology, Yamaguchi University Graduate School of Medicine, Ube, 
      Yamaguchi-ken, Japan.
FAU - Ikemoto, Kenzo
AU  - Ikemoto K
FAU - Eguchi, Satoshi
AU  - Eguchi S
FAU - Oga, Atsunori
AU  - Oga A
FAU - Kawauchi, Shigeto
AU  - Kawauchi S
FAU - Yamamoto, Yoshiaki
AU  - Yamamoto Y
FAU - Kawai, Yoshihisa
AU  - Kawai Y
FAU - Matsumoto, Hiroaki
AU  - Matsumoto H
FAU - Hara, Takahiko
AU  - Hara T
FAU - Nagao, Kazuhiro
AU  - Nagao K
FAU - Sakano, Shigeru
AU  - Sakano S
FAU - Sasaki, Kohsuke
AU  - Sasaki K
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130726
PL  - England
TA  - BJU Int
JT  - BJU international
JID - 100886721
RN  - 0 (Genetic Markers)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Carcinoma in Situ/diagnosis/*genetics
MH  - *Chromosome Aberrations
MH  - DNA Copy Number Variations/*genetics
MH  - Disease Progression
MH  - Early Detection of Cancer
MH  - Female
MH  - Genetic Markers/genetics
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/*genetics
MH  - Prognosis
MH  - Prospective Studies
MH  - Risk Assessment
MH  - Urinary Bladder Neoplasms/diagnosis/*genetics
OTO - NOTNLM
OT  - 9p21
OT  - FISH
OT  - UroVysion
OT  - non-muscle-invasive bladder cancer
OT  - prognosis
OT  - variant fraction
EDAT- 2013/07/31 06:00
MHDA- 2014/05/08 06:00
CRDT- 2013/07/30 06:00
PHST- 2013/07/30 06:00 [entrez]
PHST- 2013/07/31 06:00 [pubmed]
PHST- 2014/05/08 06:00 [medline]
AID - 10.1111/bju.12232 [doi]
PST - ppublish
SO  - BJU Int. 2014 Apr;113(4):662-7. doi: 10.1111/bju.12232. Epub 2013 Jul 26.